Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non seminomatous testicular germ cell tumors (NSGCT)

被引：0
|
作者：
Batra, A. [1 ]
Nayak, B. [2 ]
Singh, P. [2 ]
Sahoo, R. K. [2 ]
Kunhiparambath, H. [3 ]
Kaushal, S. [4 ]
Seth, A. [2 ]
Varshney, A. N. [1 ]
Raj, A. [1 ]
机构：
[1] All India Inst Med Sci, Dept Med Oncol, New Delhi, India
[2] All India Inst Med Sci, Urol, New Delhi, India
[3] All India Inst Med Sci, Dept Radiotherapy & Oncol, New Delhi, India
[4] All India Inst Med Sci, Pathol, New Delhi, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.643
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
515P
引用
收藏
页码：S778 / S778
页数：1
相关论文
共 50 条
  • [31] FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NON-SEMINOMATOUS GERM-CELL TUMORS
    SECKL, MJ
    RUSTIN, GJS
    BAGSHAWE, KD
    BRITISH JOURNAL OF CANCER, 1989, 59 (05) : 822 - 823
  • [32] Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT)
    King, Jennifer
    Ashkar, Ryan
    Kesler, Kenneth
    Althouse, Sandra K.
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance
    R de Wit
    L Collette
    R Sylvester
    PHM de Mulder
    DT Sleijfer
    WW ten Bokkel Huinink
    SB Kaye
    AT van Oosterom
    E Boven
    G Stoter
    British Journal of Cancer, 1998, 78 : 1350 - 1355
  • [34] Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors
    Aykan, Musa Baris
    Yildiran Keskin, Gulsema
    Erturk, Ismail
    Acar, Ramazan
    Kose, Ahmet Fatih
    Karadurmus, Nuri
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (01)
  • [35] Prognostic factors in patients progressing after cisplatin based chemotherapy for malignant non-seminomatous germ cell tumours
    Fosså, SD
    Stenning, SP
    Gerl, A
    Horwich, A
    Clark, PI
    Wilkinson, PM
    Jones, WG
    Williams, MV
    Oliver, RT
    Newlands, ES
    Mead, GM
    Cullen, MH
    Kaye, SB
    Rustin, GJS
    Cook, PA
    BRITISH JOURNAL OF CANCER, 1999, 80 (09) : 1392 - 1399
  • [36] Structure of residual metastases in patients with advanced testicular non-seminomatous germ cell tumors and incomplete serological and radiological response to chemotherapy
    Volkova, M., I
    Arakelyan, G. A.
    Klimov, A., V
    Fainstein, I. A.
    Sergeev, Yu S.
    Fedyanin, M. Yu
    Rumyantsev, A. A.
    Tryakin, A. A.
    Tyulyandin, A. S.
    Matveev, V. B.
    Stilidi, I. S.
    ONKOUROLOGIYA, 2022, 18 (01): : 112 - 120
  • [37] Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor
    Leao, Ricardo
    van Agthoven, Ton
    Figueiredo, Arnaldo
    Jewett, Michael A. S.
    Fadaak, Kamel
    Sweet, Joan
    Ahmad, Ardalan E.
    Anson-Cartwright, Lynn
    Chung, Peter
    Hansen, Aaron
    Warde, Padraig
    Castelo-Branco, Pedro
    O'Malley, Martin
    Bedard, Philippe L.
    Looijenga, Leendert H. J.
    Hamilton, Robert J.
    JOURNAL OF UROLOGY, 2018, 200 (01): : 126 - 134
  • [38] Prolonged survival in patients with persistently elevated tumor markers after chemotherapy for nonseminomatous germ cell cancer
    He, Z.
    Sun, Z.
    Liu, G.
    Manola, J.
    Loehrer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Prognostic significance of primary tumor morphology on progression-free survival (PFS) in patients (pts) with metastatic nonseminomatous germ cell tumors (NSGCT)
    Fedianin, M.
    Tryakin, A.
    Zakharova, T.
    Fainstein, I.
    Figurin, K.
    Polckii, B.
    Sergeev, Y.
    Garin, A.
    Tjulandin, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 308 - 308
  • [40] Major prognostic value of modeled AUChCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG
    Boyle, H.
    You, B.
    Fronton, L.
    Ribba, B.
    Girard, P.
    Tranchand, B.
    Tod, M.
    Coquelin, H.
    Droz, J.
    Flechon, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345